Conference abstract · 14 Jun 2018
Conference abstractPublished 14 Jun 2018
HIV universal vaccine
Phoenix Biomolecular Engineering Foundation, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
For many deadly viruses, there are no preventive and/or therapeutic vaccines approved by health authorities’ world-wide (e.g., Human Immunodeficiency Virus). But for some viruses prophylactic vaccines are very effective (e.g. Hepatitis B Virus). In this realm, we design, manufacture, test, and streamline in to the clinics novel viral universal vaccines (VUV). VUV have such unique features, that medical vaccination or natural infection induced immunity against some viruses (e.g., Hepatitis B Virus or Human Papilloma) upon the VUV’s administration to the infected with other, different viruses patients, is redirected against these other, newly infecting viruses (e.g., Influenza Virus). In this realm, we have bio-molecularly engineered human immunodeficiency virus universal vaccines (HIVUV). As per the Institutional Review Board approval and in compliance with the Declaration of Helsinki, all healthy donors and patients were presented with the Patients’ Bill of Rights and provided Patient Informed Consent. All the procedures were pursued by the licensed medical doctors (MDs). By flow cytometry, immunoblotting, and nuclear magnetic resonance, we have demonstrated high efficacy of HIVUV to engage HBV immunized patients’ immune system against HIV. Administration of HIVUV to blood or lymph of the HIV+ patients resulted in rapid reduction of the HIV viremia down to undetectable. It also resulted in protection of populations of CD4+ cells against HIV cytopathic decline.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 30 Dec 2024
Targeting HIV?s Weaknesses: The Quest for a Universal Vaccine
Conference abstract
Establishing a HIV vaccine research unit from scratch: The Walter Sisulu University experience
Conference abstract · 2018
Targeting conserved broadly neutralizing epitopes within HIV-1 envelope gp41 MPER as vaccine immunogens for seronegative partners of HIV-1 discordant couples
Conference abstract · 20 Feb 2017
A reasonable hope to cure HIV with the Tat Oyi vaccine: Results and follow up of a double blinded randomized phase I/IIa clinical trial in France
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectInfectious Diseases
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Marek Malecki”
